Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

Literature DB >> 21545551

Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

E Jensen-Jarolim, J Singer.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21545551 PMCID： PMC4429181 DOI： 10.1111/j.1365-2222.2011.03764.x

Source DB: PubMed Journal: Clin Exp Allergy ISSN： 0954-7894 Impact factor: 5.018

× No keyword cloud information.

39 in total

Review 1. New challenges to medicare beneficiary access to mAbs.

Authors: Joshua Cohen; Andrew Wilson
Journal: MAbs Date: 2009 Jan-Feb Impact factor: 5.857

2. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.

Authors: S L Fu; J Pierre; T A Smith-Norowitz; M Hagler; W Bowne; M R Pincus; C M Mueller; M E Zenilman; M H Bluth
Journal: Clin Exp Immunol Date: 2008-09 Impact factor: 4.330

Review 3. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.

Authors: S Danese; J-F Colombel; W Reinisch; P J Rutgeerts
Journal: Aliment Pharmacol Ther Date: 2011-02-15 Impact factor: 8.171

4. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.

Authors: Sophia N Karagiannis; Qin Wang; Nick East; Frances Burke; Stephane Riffard; Marguerite G Bracher; Richard G Thompson; Stephen R Durham; Lawrence B Schwartz; Frances R Balkwill; Hannah J Gould
Journal: Eur J Immunol Date: 2003-04 Impact factor: 5.532

5. Diagnosis and management of drug hypersensitivity reactions.

Authors: Antonino Romano; Maria J Torres; Mariana Castells; Maria L Sanz; Miguel Blanca
Journal: J Allergy Clin Immunol Date: 2011-03 Impact factor: 10.793

6. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.

Authors: Stefan Lohse; Stefanie Derer; Thomas Beyer; Katja Klausz; Matthias Peipp; Jeanette H W Leusen; Jan G J van de Winkel; Michael Dechant; Thomas Valerius
Journal: J Immunol Date: 2011-02-11 Impact factor: 5.422

7. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.

Authors: Helena Pavlakovic; Jürgen Becker; Romulo Albuquerque; Jörg Wilting; Jayakrishna Ambati
Journal: Ann N Y Acad Sci Date: 2010-10 Impact factor: 5.691

Review 8. Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Authors: Louis M Weiner; Rishi Surana; Shangzi Wang
Journal: Nat Rev Immunol Date: 2010-05 Impact factor: 53.106

9. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.

Authors: Sophia N Karagiannis; Marguerite G Bracher; Rebecca L Beavil; Andrew J Beavil; James Hunt; Natalie McCloskey; Richard G Thompson; Nicholas East; Frances Burke; Brian J Sutton; David Dombrowicz; Frances R Balkwill; Hannah J Gould
Journal: Cancer Immunol Immunother Date: 2007-07-27 Impact factor: 6.968

10. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

Authors: Sophia N Karagiannis; Marguerite G Bracher; James Hunt; Natalie McCloskey; Rebecca L Beavil; Andrew J Beavil; David J Fear; Richard G Thompson; Nicholas East; Frances Burke; Robert J Moore; David D Dombrowicz; Frances R Balkwill; Hannah J Gould
Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422

5 in total

Review 1. IgE immunotherapy against cancer.

Authors: Lai Sum Leoh; Tracy R Daniels-Wells; Manuel L Penichet
Journal: Curr Top Microbiol Immunol Date: 2015 Impact factor: 4.291